Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: AstraZeneca UK Ltd., 600 Capability Green, Luton, LU1 3LU, UK
Casodex 150 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). White. |
Each tablet contains 150 mg bicalutamide (INN).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bicalutamide |
Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. |
| List of Excipients |
|---|
|
Tablet Core: Lactose monohydrate Film-coating material: Hypromellose |
PVC/Aluminium foil blister pack comprising strips of 5, 10 and 14 tablets to give pack sizes of 10, 20, 30, 40, 50, 80, 90, 100, 200 or 14, 28, 56, 84, 140 and 280 tablets.
Not all pack sizes may be marketed.
AstraZeneca UK Ltd., 600 Capability Green, Luton, LU1 3LU, UK
PL 17901/0006
Date of first authorisation: 18th June 2000
Date of latest renewal: 16th June 2004
| Drug | Countries | |
|---|---|---|
| CASODEX | Austria, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
